By physician referral or invitation only

EASINESS Prospective molecular analysis In metastatic breast cancer patients treated with antibody drug conjugates

The purpose of this study is to determine if it is possible to identify biomarkers that tell us what type of response a person with metastatic breast cancer (MBC) will have to "antibody-drug conjugates" (ADCs).

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Lisa Carey
LCCC - Clinical Trials

Study Type

Clinical or Medical
Registry

Study Topics

Cancer (Breast)

IRB Number

23-1296

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.